XT
EDIT icon

XTX Topco’s Editas Medicine EDIT Stock Holding History

XTX Topco’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$77.7K Sell
23,968
-38,468
-62% -$112K ﹤0.01% 3602
2026
Q1 		$154K Sell
62,436
-184,170
-75% -$390K ﹤0.01% 2940
2025
Q4 		$506K Sell
246,606
-13,507
-5% -$39K 0.01% 1593
2025
Q3 		$903K Buy
260,113
+127,176
+96% +$355K 0.05% 647
2025
Q2 		$292K Sell
132,937
-342,444
-72% -$560K 0.01% 1452
2025
Q1 		$551K Buy
475,381
+370,325
+353% +$545K 0.03% 956
2024
Q4 		$133K Buy
105,056
+52,498
+100% +$134K 0.01% 1703
2024
Q3 		$179K Buy
+52,558
New +$229K 0.01% 1481
2024
Q2 		– Sell
-21,698
Closed -$161K – 2012
2024
Q1 		$161K Sell
21,698
-7,306
-25% -$60.7K 0.02% 1242
2023
Q4 		$294K Sell
29,004
-9,778
-25% -$85.8K 0.06% 638
2023
Q3 		$303K Sell
38,782
-19,532
-33% -$167K 0.05% 725
2023
Q2 		$480K Buy
+58,314
New +$508K 0.09% 396
2023
Q1 		– Sell
-33,978
Closed -$301K – 1377
2022
Q4 		$301K Buy
33,978
+22,070
+185% +$242K 0.06% 577
2022
Q3 		$146K Buy
+11,908
New +$186K 0.04% 870
2021
Q2 		– Sell
-14,126
Closed -$593K – 872
2021
Q1 		$593K Buy
+14,126
New +$805K 0.29% 56

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

XTX Topco's EDIT Position: Q2 2026 in Review

XTX Topco reduced its Editas Medicine (EDIT) stake by 62% in Q2 2026, selling an estimated $112K and leaving 23,968 shares worth $77.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3602.

XTX Topco first reported a position in EDIT in Q1 2021 and has held it in 15 quarters since. The position peaked at $903K in Q3 2025. 214 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • XTX Topco held 23,968 shares of Editas Medicine worth $77.7K as of Q2 2026.
  • XTX Topco sold 38,468 Editas Medicine shares in Q2 2026, an estimated $112K.
  • Editas Medicine made up ﹤0.01% of XTX Topco's portfolio in Q2 2026, its #3602 holding.
  • XTX Topco first reported a position in Editas Medicine in Q1 2021 and has held it in 15 quarters since.
  • XTX Topco's Editas Medicine position peaked at $903K in Q3 2025.
  • 214 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.